Ovarian Cancer

Recent reports from two drug companies that had been conducing separate clinical trials to evaluate cancer treatments reveal that the trials were halted due to the deaths of six participants, including one child.  One of the trials had focused on assessing a potential treatment...

Researchers at Southern Illinois University (SIU) may be on the way to determining how cannabis can help cure ovarian cancer, reported the Daily Egyptian, the student-run news organization for the SIU community. Conducted by the Cannabis Science Center, the research was led...

Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) announced initial efficacy and safety data from the ongoing Phase 1b trial of ZN-c3 combined with chemotherapy in patients with platinum-resistant or -refractory ovarian cancer.  Data were reviewed at the American Association of...

Zai Lab Limited (NASDAQ: ZLAB) presented data from the Phase 3 PRIME study of Zejula (niraparib) as maintenance therapy in Chinese ovarian cancer patients. Zejula demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with a...

ImmunoGen Inc (NASDAQ: IMGN) shared full results from the SORAYA trial evaluating mirvetuximab in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer patients, previously treated with Roche Holdings AG's (OTC: RHHBY) Avastin (bevacizumab). ...

ImmunoGen Inc (NASDAQ: IMGN) shares have gained more than 30% during premarket trading in reaction to positive topline data from the SORAYA trial of mirvetuximab soravtansine for ovarian cancer. The trial is evaluating mirvetuximab as monotherapy in patients with folate receptor...

Shattuck Labs Inc (NASDAQ: STTK) and Takeda Pharmaceutical Co Ltd (NYSE: TAK) mutually agreed to terminate the Collaboration Agreement for SL-279252 and SL-115154. The agreement was initially executed in 2017, under which Takeda had options for up to four molecules. Shattuck...

Bicycle Therapeutics plc (NASDAQ: BCYC) has reported interim Phase I trial results for BT5528 and preliminary findings from the ongoing dose-escalation portion of the BT8009 trial. Two BT5528 monotherapy urothelial patients were dosed. Both were observed to have tumor reductions...

Prelude Therapeutics Inc (NASDAQ: PRLD) has announced data from the dose-escalation portions of Phase 1 trials of PRT543 and PRT811.  The data will be featured at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. PRT543...

Verastem Oncology Inc (NASDAQ: VSTM) stock is trading higher after updated data from the ongoing Phase 1/2 FRAME study.  The investigator-sponsored study is investigating VS-6766, Verastem's RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor, in patients...

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) announced four e-poster presentations at the European Society for Medical Oncology (ESMO21) Virtual Conference 2021.  The presentations include updated preliminary results from the ongoing Phase 1b/2 study of rebastinib plus paclitaxel in...

Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced that data from the Phase 2 trial of relacorilant plus nab-paclitaxel were presented at the European Society for Medical Oncology (ESMO21) Congress 2021. The trial included 178 patients with recurrent platinum-resistant...

Mersana Therapeutics Inc (NASDAQ: MRSN) stock is moving lower during the market trading session. Investors are reacting to interim data from the ovarian cancer Phase 1 trial evaluating Upifitamab Rilsodotin (UpRi, previously XMT-1536). See the related Company presentation here. Complete...

The FDA has signed off Anixa Biosciences Inc's (NASDAQ: ANIX) application for its CAR-T (Chimeric Antigen Receptor-T cell) therapy, developed in partnership with Moffitt Cancer Center. Anixa Biosciences has an exclusive worldwide license to the technology. The therapeutic...

The FDA has granted Fast Track designation to Sutro Biopharma Inc's (NASDAQ: STRO) STRO-002 for ovarian cancer. The designation covers platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients who have received one to three prior lines of...